Expert Talk

Industry-Academia Interactions

In the Indian scenario, teachers are overburdened and are involved in too many non-academic activities resulting in poor research output. There are only a handful of universities and institutions with a serious focus on research.

M&A in Pharma

Expert Views

Sujay J Shetty, Associate Director, Pharma Life Sciences , Advisory Corporate Finance, PriceWaterhousecoopers, India.
Ganesh Nayak, Executive Director, Zydus Cadila, India
Joseph Manoj Victor, Senior Research Analyst, Healthcare Practice, Frost & Sullivan, India.
R B Smarta, Founder and Managing Director, Interlink Marketing Consultancy Pvt. Ltd.

M&A and Partnerships in Pharma

Rising opportunities

Because R&D productivity is a problem for pharma the partnering opportunities are basically seen in licensing and acquisitions.

M&A and Partnerships in Pharma

Indian scenario

India's growing respect and legal / regulatory framework for IPR, favourable economic policies resulting into attractive investment destination and availability of huge talent pool for sustaining and growing operations is making India an attractive destination for multinationals now.

Biopharmaceutical Manufacturing

The challenges

Asia is emerging strongly in the area of biopharmaceutical manufacturing. More and more companies are confident of offering quality products and / or services. In the span of past two years, the perception of having an Asian manufacturing partner has been very positive, with nearly 80 per cent of small and large companies eyeing to outsource manufacturing to Asian biopharmaceutical companies.

Public Private Partnerships

PPPs is being seen as an effective strategy to reduce pipeline stress and also keep the spiralling cost of drug discovery and development under control.

Effective Interactions

Institute - Industry

Clinical Trials in China

Partnerships and Innovation

The growth factors

Developing a product pipeline is being considered seriously and will be an essential factor for the growth of the Indian pharma market.

Biosimilars

What lies ahead?

Biosimilars will eventually bring down the cost of biological medicines and in doing so will expand the market.